Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting
Purpose The aim of this study was to investigate the sustained intraocular pressure (IOP) elevation after repeated anti-VEGF intravitreal injections (IVI) in patients with diabetic macular edema (DME). Methods A retrospective study included 140 eyes without prior glaucoma, treated with at least thre...
Gespeichert in:
| Veröffentlicht in: | Graefe's archive for clinical and experimental ophthalmology 2017-11, Vol.255 (11), p.2165-2171 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2171 |
|---|---|
| container_issue | 11 |
| container_start_page | 2165 |
| container_title | Graefe's archive for clinical and experimental ophthalmology |
| container_volume | 255 |
| creator | Vo Kim, S. Fajnkuchen, F. Sarda, V. Qu-Knafo, L. Bodaghi, B. Giocanti-Aurégan, A. |
| description | Purpose
The aim of this study was to investigate the sustained intraocular pressure (IOP) elevation after repeated anti-VEGF intravitreal injections (IVI) in patients with diabetic macular edema (DME).
Methods
A retrospective study included 140 eyes without prior glaucoma, treated with at least three anti-VEGF injections for DME between 2012 and 2016. IOP elevation was defined by an increase above baseline IOP by ≥6 mmHg. Baseline IOP was defined as the mean of IOP values before treatment initiation. Three groups were differentiated: group 1 without IOP elevation, groups 2 and 3 with IOP elevation and IOP |
| doi_str_mv | 10.1007/s00417-017-3782-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1931713557</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1951228670</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-2e4fd717e63e88d4af30e8fb4b9937e2ca416dba03db91a12556ed3b98e1025f3</originalsourceid><addsrcrecordid>eNp1kcGKFDEQhoMo7uzqA3iRgBcvramku9N9lGXVhQUPKuytqe5UZjP0dMYkPcu8lk9omh5FBA9FUanv_yvwM_YKxDsQQr-PQpSgC5FL6UYWpydsA6WqCi3k_VO2EVpC0Sh5f8EuY9yJjKsKnrML2TQKalAb9vPrHBO6iQx3Uwroh3nEwA-BYpwDcRrpiMn5Ka85nSjyFAhTxh9delg1R7e8jXnY0bCwkXvLcUquOGJcDWkyPj3Q6DK3Df4xay0OyQducxmHPSU38D2ecUN7XE4iX6yL0VnikVJy0_YFe2ZxjPTy3K_Y9483364_F3dfPt1ef7grBqVlKiSV1mjQVCtqGlOiVYIa25d92ypNcsASatOjUKZvAUFWVU1G9W1DIGRl1RV7u_oegv8xU0zd3sWBxhEn8nPsoFWgQVWVzuibf9Cdn8OUf5epCqRsai0yBSs1BB9jINsdgttjOHUguiXQbg20y4F2S6DdKWten53nfk_mj-J3ghmQKxDzatpS-Ov0f11_AbVgsOU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1951228670</pqid></control><display><type>article</type><title>Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Vo Kim, S. ; Fajnkuchen, F. ; Sarda, V. ; Qu-Knafo, L. ; Bodaghi, B. ; Giocanti-Aurégan, A.</creator><creatorcontrib>Vo Kim, S. ; Fajnkuchen, F. ; Sarda, V. ; Qu-Knafo, L. ; Bodaghi, B. ; Giocanti-Aurégan, A.</creatorcontrib><description>Purpose
The aim of this study was to investigate the sustained intraocular pressure (IOP) elevation after repeated anti-VEGF intravitreal injections (IVI) in patients with diabetic macular edema (DME).
Methods
A retrospective study included 140 eyes without prior glaucoma, treated with at least three anti-VEGF injections for DME between 2012 and 2016. IOP elevation was defined by an increase above baseline IOP by ≥6 mmHg. Baseline IOP was defined as the mean of IOP values before treatment initiation. Three groups were differentiated: group 1 without IOP elevation, groups 2 and 3 with IOP elevation and IOP <21 mmHg (group 2) and ≥21 mmHg (group 3). Rate and several risk factors of IOP elevation were assessed and compared between the three groups.
Results
IOP elevation occurred in ten eyes (7.1%). IOP was <21 mmHg in six eyes and ≥21 mmHg in four eyes. Statistically significant associations were found between IOP elevation and the number of injections, and HbA1c level. Two patients required local hypotonic treatment.
Conclusions
In a real-life setting, we confirmed in eyes with center-involved DME without prior glaucoma or IOP elevation that repeated anti-VEGF IVI may increase the risk of sustained IOP elevation in about 7% of eyes.</description><identifier>ISSN: 0721-832X</identifier><identifier>EISSN: 1435-702X</identifier><identifier>DOI: 10.1007/s00417-017-3782-y</identifier><identifier>PMID: 28831613</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors - administration & dosage ; Angiogenesis Inhibitors - adverse effects ; Bevacizumab - administration & dosage ; Bevacizumab - adverse effects ; Diabetes ; Diabetes mellitus ; Diabetic retinopathy ; Diabetic Retinopathy - drug therapy ; Edema ; Female ; Follow-Up Studies ; Glaucoma ; Humans ; Immunotherapy ; Intraocular Pressure - drug effects ; Intraocular Pressure - physiology ; Intravitreal Injections ; Macular Edema - diagnosis ; Macular Edema - drug therapy ; Macular Edema - etiology ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Monoclonal antibodies ; Ocular Hypertension - chemically induced ; Ocular Hypertension - physiopathology ; Ophthalmology ; Pressure ; Ranibizumab - administration & dosage ; Ranibizumab - adverse effects ; Retinal Disorders ; Retrospective Studies ; Risk Factors ; Statistical analysis ; Time Factors ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><ispartof>Graefe's archive for clinical and experimental ophthalmology, 2017-11, Vol.255 (11), p.2165-2171</ispartof><rights>Springer-Verlag GmbH Germany 2017</rights><rights>Graefe's Archive for Clinical and Experimental Ophthalmology is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-2e4fd717e63e88d4af30e8fb4b9937e2ca416dba03db91a12556ed3b98e1025f3</citedby><cites>FETCH-LOGICAL-c372t-2e4fd717e63e88d4af30e8fb4b9937e2ca416dba03db91a12556ed3b98e1025f3</cites><orcidid>0000-0002-7918-7845</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00417-017-3782-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00417-017-3782-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28831613$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vo Kim, S.</creatorcontrib><creatorcontrib>Fajnkuchen, F.</creatorcontrib><creatorcontrib>Sarda, V.</creatorcontrib><creatorcontrib>Qu-Knafo, L.</creatorcontrib><creatorcontrib>Bodaghi, B.</creatorcontrib><creatorcontrib>Giocanti-Aurégan, A.</creatorcontrib><title>Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting</title><title>Graefe's archive for clinical and experimental ophthalmology</title><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><description>Purpose
The aim of this study was to investigate the sustained intraocular pressure (IOP) elevation after repeated anti-VEGF intravitreal injections (IVI) in patients with diabetic macular edema (DME).
Methods
A retrospective study included 140 eyes without prior glaucoma, treated with at least three anti-VEGF injections for DME between 2012 and 2016. IOP elevation was defined by an increase above baseline IOP by ≥6 mmHg. Baseline IOP was defined as the mean of IOP values before treatment initiation. Three groups were differentiated: group 1 without IOP elevation, groups 2 and 3 with IOP elevation and IOP <21 mmHg (group 2) and ≥21 mmHg (group 3). Rate and several risk factors of IOP elevation were assessed and compared between the three groups.
Results
IOP elevation occurred in ten eyes (7.1%). IOP was <21 mmHg in six eyes and ≥21 mmHg in four eyes. Statistically significant associations were found between IOP elevation and the number of injections, and HbA1c level. Two patients required local hypotonic treatment.
Conclusions
In a real-life setting, we confirmed in eyes with center-involved DME without prior glaucoma or IOP elevation that repeated anti-VEGF IVI may increase the risk of sustained IOP elevation in about 7% of eyes.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Angiogenesis Inhibitors - adverse effects</subject><subject>Bevacizumab - administration & dosage</subject><subject>Bevacizumab - adverse effects</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetic retinopathy</subject><subject>Diabetic Retinopathy - drug therapy</subject><subject>Edema</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glaucoma</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Intraocular Pressure - drug effects</subject><subject>Intraocular Pressure - physiology</subject><subject>Intravitreal Injections</subject><subject>Macular Edema - diagnosis</subject><subject>Macular Edema - drug therapy</subject><subject>Macular Edema - etiology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Ocular Hypertension - chemically induced</subject><subject>Ocular Hypertension - physiopathology</subject><subject>Ophthalmology</subject><subject>Pressure</subject><subject>Ranibizumab - administration & dosage</subject><subject>Ranibizumab - adverse effects</subject><subject>Retinal Disorders</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Statistical analysis</subject><subject>Time Factors</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><issn>0721-832X</issn><issn>1435-702X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kcGKFDEQhoMo7uzqA3iRgBcvramku9N9lGXVhQUPKuytqe5UZjP0dMYkPcu8lk9omh5FBA9FUanv_yvwM_YKxDsQQr-PQpSgC5FL6UYWpydsA6WqCi3k_VO2EVpC0Sh5f8EuY9yJjKsKnrML2TQKalAb9vPrHBO6iQx3Uwroh3nEwA-BYpwDcRrpiMn5Ka85nSjyFAhTxh9delg1R7e8jXnY0bCwkXvLcUquOGJcDWkyPj3Q6DK3Df4xay0OyQducxmHPSU38D2ecUN7XE4iX6yL0VnikVJy0_YFe2ZxjPTy3K_Y9483364_F3dfPt1ef7grBqVlKiSV1mjQVCtqGlOiVYIa25d92ypNcsASatOjUKZvAUFWVU1G9W1DIGRl1RV7u_oegv8xU0zd3sWBxhEn8nPsoFWgQVWVzuibf9Cdn8OUf5epCqRsai0yBSs1BB9jINsdgttjOHUguiXQbg20y4F2S6DdKWten53nfk_mj-J3ghmQKxDzatpS-Ov0f11_AbVgsOU</recordid><startdate>20171101</startdate><enddate>20171101</enddate><creator>Vo Kim, S.</creator><creator>Fajnkuchen, F.</creator><creator>Sarda, V.</creator><creator>Qu-Knafo, L.</creator><creator>Bodaghi, B.</creator><creator>Giocanti-Aurégan, A.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7918-7845</orcidid></search><sort><creationdate>20171101</creationdate><title>Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting</title><author>Vo Kim, S. ; Fajnkuchen, F. ; Sarda, V. ; Qu-Knafo, L. ; Bodaghi, B. ; Giocanti-Aurégan, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-2e4fd717e63e88d4af30e8fb4b9937e2ca416dba03db91a12556ed3b98e1025f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Angiogenesis Inhibitors - adverse effects</topic><topic>Bevacizumab - administration & dosage</topic><topic>Bevacizumab - adverse effects</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetic retinopathy</topic><topic>Diabetic Retinopathy - drug therapy</topic><topic>Edema</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glaucoma</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Intraocular Pressure - drug effects</topic><topic>Intraocular Pressure - physiology</topic><topic>Intravitreal Injections</topic><topic>Macular Edema - diagnosis</topic><topic>Macular Edema - drug therapy</topic><topic>Macular Edema - etiology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Ocular Hypertension - chemically induced</topic><topic>Ocular Hypertension - physiopathology</topic><topic>Ophthalmology</topic><topic>Pressure</topic><topic>Ranibizumab - administration & dosage</topic><topic>Ranibizumab - adverse effects</topic><topic>Retinal Disorders</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Statistical analysis</topic><topic>Time Factors</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vo Kim, S.</creatorcontrib><creatorcontrib>Fajnkuchen, F.</creatorcontrib><creatorcontrib>Sarda, V.</creatorcontrib><creatorcontrib>Qu-Knafo, L.</creatorcontrib><creatorcontrib>Bodaghi, B.</creatorcontrib><creatorcontrib>Giocanti-Aurégan, A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vo Kim, S.</au><au>Fajnkuchen, F.</au><au>Sarda, V.</au><au>Qu-Knafo, L.</au><au>Bodaghi, B.</au><au>Giocanti-Aurégan, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting</atitle><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle><stitle>Graefes Arch Clin Exp Ophthalmol</stitle><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><date>2017-11-01</date><risdate>2017</risdate><volume>255</volume><issue>11</issue><spage>2165</spage><epage>2171</epage><pages>2165-2171</pages><issn>0721-832X</issn><eissn>1435-702X</eissn><abstract>Purpose
The aim of this study was to investigate the sustained intraocular pressure (IOP) elevation after repeated anti-VEGF intravitreal injections (IVI) in patients with diabetic macular edema (DME).
Methods
A retrospective study included 140 eyes without prior glaucoma, treated with at least three anti-VEGF injections for DME between 2012 and 2016. IOP elevation was defined by an increase above baseline IOP by ≥6 mmHg. Baseline IOP was defined as the mean of IOP values before treatment initiation. Three groups were differentiated: group 1 without IOP elevation, groups 2 and 3 with IOP elevation and IOP <21 mmHg (group 2) and ≥21 mmHg (group 3). Rate and several risk factors of IOP elevation were assessed and compared between the three groups.
Results
IOP elevation occurred in ten eyes (7.1%). IOP was <21 mmHg in six eyes and ≥21 mmHg in four eyes. Statistically significant associations were found between IOP elevation and the number of injections, and HbA1c level. Two patients required local hypotonic treatment.
Conclusions
In a real-life setting, we confirmed in eyes with center-involved DME without prior glaucoma or IOP elevation that repeated anti-VEGF IVI may increase the risk of sustained IOP elevation in about 7% of eyes.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>28831613</pmid><doi>10.1007/s00417-017-3782-y</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-7918-7845</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0721-832X |
| ispartof | Graefe's archive for clinical and experimental ophthalmology, 2017-11, Vol.255 (11), p.2165-2171 |
| issn | 0721-832X 1435-702X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1931713557 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Aged, 80 and over Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Bevacizumab - administration & dosage Bevacizumab - adverse effects Diabetes Diabetes mellitus Diabetic retinopathy Diabetic Retinopathy - drug therapy Edema Female Follow-Up Studies Glaucoma Humans Immunotherapy Intraocular Pressure - drug effects Intraocular Pressure - physiology Intravitreal Injections Macular Edema - diagnosis Macular Edema - drug therapy Macular Edema - etiology Male Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Ocular Hypertension - chemically induced Ocular Hypertension - physiopathology Ophthalmology Pressure Ranibizumab - administration & dosage Ranibizumab - adverse effects Retinal Disorders Retrospective Studies Risk Factors Statistical analysis Time Factors Vascular endothelial growth factor Vascular Endothelial Growth Factor A - antagonists & inhibitors |
| title | Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T22%3A48%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sustained%20intraocular%20pressure%20elevation%20in%20eyes%20treated%20with%20intravitreal%20injections%20of%20anti-vascular%20endothelial%20growth%20factor%20for%20diabetic%20macular%20edema%20in%20a%20real-life%20setting&rft.jtitle=Graefe's%20archive%20for%20clinical%20and%20experimental%20ophthalmology&rft.au=Vo%20Kim,%20S.&rft.date=2017-11-01&rft.volume=255&rft.issue=11&rft.spage=2165&rft.epage=2171&rft.pages=2165-2171&rft.issn=0721-832X&rft.eissn=1435-702X&rft_id=info:doi/10.1007/s00417-017-3782-y&rft_dat=%3Cproquest_cross%3E1951228670%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1951228670&rft_id=info:pmid/28831613&rfr_iscdi=true |